NOS2 and cancer: In addition, the local expression of key pathway enzymes (ARG1, ARG2, DDAH1, DDAH2, NOS2, ODC1, PRMT1, and PRMT5), as potential therapeutic targets, was evaluated in reference to cancer pathology.